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Abstract
Objective: Pro-inflammatory cytokines like Interleukin-1 beta (IL-1b) have been implicated in the pathophysiology of
migraine and inflammatory pain. The trigeminal ganglion and calcitonin gene-related peptide (CGRP) are crucial
components in the pathophysiology of primary headaches. 5-HT1B/D receptor agonists, which reduce CGRP release, and
cyclooxygenase (COX) inhibitors can abort trigeminally mediated pain. However, the cellular source of COX and the
interplay between COX and CGRP within the trigeminal ganglion have not been clearly identified.
Methods and Results: 1. We used primary cultured rat trigeminal ganglia cells to assess whether IL-1b can induce the
expression of COX-2 and which cells express COX-2. Stimulation with IL-1b caused a dose and time dependent induction of
COX-2 but not COX-1 mRNA. Immunohistochemistry revealed expression of COX-2 protein in neuronal and glial cells. 2.
Functional significance was demonstrated by prostaglandin E2 (PGE2) release 4 hours after stimulation with IL-1b, which
could be aborted by a selective COX-2 (parecoxib) and a non-selective COX-inhibitor (indomethacin). 3. Induction of CGRP
release, indicating functional neuronal activation, was seen 1 hour after PGE2 and 24 hours after IL-1b stimulation.
Immunohistochemistry showed trigeminal neurons as the source of CGRP. IL-1b induced CGRP release was blocked by
parecoxib and indomethacin, but the 5-HT1B/D receptor agonist sumatriptan had no effect.
Conclusion: We identified a COX-2 dependent pathway of cytokine induced CGRP release in trigeminal ganglia neurons that
is not affected by 5-HT1B/D receptor activation. Activation of neuronal and glial cells in the trigeminal ganglion by IL-b leads
to an elevated expression of COX-2 in these cells. Newly synthesized PGE2 (by COX-2) in turn activates trigeminal neurons to
release CGRP. These findings support a glia-neuron interaction in the trigeminal ganglion and demonstrate a sequential link
between COX-2 and CGRP. The results could help to explain the mechanism of action of COX-2 inhibitors in migraine.
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Introduction
Pro-inflammatory cytokines have been linked to inflammation
and pain [1]. Interleukin-1b (IL-1b), interleukin-6 and tumor
necrosis factor-a (TNFa) are known to induce hyperalgesia in rats
[2–4]. Cytokines also seem to play an important role in
pathophysiological mechanisms involved in migraine headache.
Among others, IL-1b and TNFa levels were elevated in jugular vein
blood during migraine attacks [5,6]. Plasma levels of IL-6 were also
increased in patients with migraine compared to healthy controls
[7]. Furthermore, enhanced expression of IL-1b was found in the
meninges in an experimental animal model related to migraine [8].
The trigeminal system, neuropeptides and inflammatory
mediators are key players in the pathophysiology of migraine.
Activation of perivascular trigeminal nerves within meninges
causes the release of calcitonin gene-related peptide (CGRP) and
other peptides e.g. substance P [9,10]. This leads to a series of
peripheral and central events such as vasodilatation, plasma
protein extravasation [11] and neuronal activation [12].
CGRP is classified as the most important neuromediator in the
pathophysiology of migraine and other primary headaches. It is
believed not only to be involved in dilation of cerebral and dural
blood vessels but also in release of inflammatory mediators from
mast cells and transmission of nociceptive information [13]. In
clinical studies, plasma levels of CGRP can be found to be elevated
during migraine and cluster headache attacks [14,15]. Intravenous
injection of CGRP induces a typical headache in migraineurs [16]
and CGRP receptor antagonists (BIBN4096BS/MK-0974) can
abort attacks [17,18].
On a cellular basis in an experimental cell culture model,
stimulation of trigeminal ganglia neurons with potassium chloride,
capsaicin or a cocktail of inflammatory mediators used to mimic
neurogenic inflammation resulted in an elevated CGRP release in
these cells. Stimulus induced CGRP release could be repressed by
the 5-HT1B/D agonist sumatriptan [19], which is used in acute
migraine treatment, and furthermore by botulinum toxin type A
[20] and topiramate [21], two substances proved to be effective in
migraine prophylaxis. Stimulation with TNFa increased the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17360synthesis and release of CGRP in trigeminal ganglia neurons [22]
indicating a link between cytokines and CGRP release.
In addition to CGRP, Cyclooxygenases (COX) are important
peripheral mediators of inflammation and pain. COX enzymes
are involved in migraine pathomechanisms as non-selective [23]
and selective COX-2 inhibitors [24,25] can abort attacks. The
constitutively expressed isoform COX-1 and the inducible enzyme
COX-2 both synthesize prostaglandins [26] which are involved in
neuronal sensitization phenomena induced by Interleukin 1b
(IL-1b) [27]. However, the precise pathophysiological role of
COX and its reaction product prostaglandin E2 (PGE2)i n
migraine remain unclear.
We investigated the expression of COX and its cellular sources
in cultured trigeminal ganglia cells (TGC) upon stimulation with
the cytokine IL-1b. We further assessed the effects of IL-1b on
CGRP release in vitro. Based on the efficacy of COX- inhibitors to
abort migraine we hypothesized that induced COX-2 expression
leads to PGE2 production in TGC which may have an effect on
CGRP release.
Materials and Methods
Animals
We used 3 days old male and female Sprague Dawley rats
(Charles River, Sulzheim, Germany). All animals were kept under
standard laboratory housing conditions with a 12-h light–dark
cycle and with an adult female Sprague Dawley rat (Charles River,
Sulzheim, Germany) with free access to food and water. For cell
culture procedures 3 day old rats were anaesthetized with an
isoflurane vaporizer (4%) and decapitated. All animal work was
carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC) regarding
the care and use of animals for experimental procedures. The
sacrifice of the rats and extraction of their brains was reported to
and approved by the Landesamt fu ¨r Gesundheit und Soziales
Berlin (LaGeSo; T0322/96).
Cell culture
Trigeminal ganglia cell culture was established as previously
described [28] with minor modifications. In brief, trigeminal
ganglia were dissected from 3 day old male and female Sprague
Dawley rats (Charles River, Sulzheim, Germany). The cells were
incubated for 90 min at 37uC in 10 ml dissociation medium
(modified eagles medium; Biochrom, Berlin, Germany; with 10%
bovine serum, 10 mM HEPES, 44 mM glucose, 100 U penicillin
+ streptomycin, 2 mM glutamine, 100 IE insulin/l) containing
collagenase/dispase (final concentration 100 mg/ml) (Boehringer
Mannheim, Germany), rinsed twice with phosphate buffered
saline (PBS) 0.1 M and again incubated with trypsin/EDTA
(0.05%/0.02% w/v in PBS) for 30 min for dissociation. Subse-
quently, cells were rinsed twice with PBS and once with
dissociation medium, dissociated by Pasteur pipette and pelleted
by centrifugation at 21006g for 2 min at 21uC. After suspension
in starter medium (Invitrogen, Karlsruhe, Germany) plus 1%
penicillin/streptomycin, 0,25% L-glutamine, 2% B27-supplement,
0,1% 25 mM glutamate, 2.5 mM calcium chloride and 100 ng/
ml NGF-b, cells were plated in 24 well plates and filled to 500 ml
with starter medium at a density of 0.5610
26 cells/cm
2 (equates
approximately 2 ganglia/well). Cells used for immunohistochem-
istry were seeded on round glass cover slips previously inserted in
the well plates. Wells were pretreated by incubation with poly-l-
lysin (5% w/v in PBS) for 90 minutes at 4uC, then rinsed with
PBS, followed by incubation with coating medium (dissociation
medium with 1% w/v collagen G) for 90 minutes at 37uC in the
incubator. After that, the wells were rinsed twice with PBS and
filled with starter medium in which cells were seeded. Cytosine
arabinoside (final concentration 10 mM; Sigma Aldrich, Munich,
Germany) was added at day 1 and day 3 to minimize growth of
non-neuronal cells. Cultures were kept at 37uC and 5% CO2 and
fed with neurobasal medium + B27 medium every second day by
replacing 50% of the medium. Condition of cultures was assessed
by light microscopy, cell types by cell morphology and
immunohistochemistry (with antibodies against glial fibrillary
acidic protein (GFAP) for glial cells and b-tubulin III for neurons).
Cell damage was monitored by life-death assays. Stimulation
experiments and immunohistochemistry were performed on day 6.
Quantitative real-time RT-PCR
Cultured trigeminal ganglia cells were stimulated with recombi-
nant rat IL-1b (R&D Systems, Wiesbaden, Germany; 10 ng/ml,
diluted in PBS 0.1 M) or vehicle (0.1 M PBS). In experiments with
the IL-1 receptor antagonist (IL-1ra, R&D Systems, Wiesbaden,
Germany) cells were preincubated with 10 mg/ml IL-1ra 15 min
prior to stimulation with 10 ng/ml IL-1b. The supernatant was
removed carefully with a pipette at certain time points (1.5, 3 and
6 hours). Total cellular RNA of two equally treated wells was
extracted using Trizol reagent (Invitrogen, Karlsruhe, Germany)
according to the supplier’s manual. RNA preparation and cDNA
synthesis were performed as described previously by our laboratory
[29]. Real time reverse transcription quantitative polymerase chain
reaction (RT-PCR) was carried out on a LightCycler (Roche
Diagnostics GmbH, Mannheim, Germany) using the LC-Fast Start
DNA Master SYBR Green I kit as recommended by the
manufacturer and primers for CGRP, COX-1, COX-2 and
GAPDH (Promega, Mannheim, German). The DNA polymerase
was heat activated at 95uC followed by thermal cycling until
saturation. Table 1 lists the used primer sequences, cycling
conditions and primer efficacies. Specificity of all primers was
confirmed by sequencing of amplicons. Each essay was run in
duplicate. LightCycler Relative Quantification Software was used
for amplification, detection and determination of the crossing point.
The relative expression ratio for each time point of the measured
genes was calculated from the previously determined RT-PCR
efficiencies (E) of the primers and the crossing point deviation (DCP)
of the sample (treated with IL-1b or vehicle) versus the control
(0 hour time point) with normalization for RNA preparation and
reverse transcriptase reaction on the basis of its mRNA content of
the housekeeping gene Glycerinaldehyd-3-phosphat-Dehydroge-
nase [30].
Western blot analysis
Trigeminal ganglia cells incubated 6 hours with IL-1b (10 ng/
ml) or vehicle were homogenized with an electric grinder on ice in
250 ml buffer containing 10 mM HEPES (pH 7.4), 0.42 M KCl,
5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM
DTT and a protease inhibitor cocktail (diluted 1:50 in PBS; Sigma
Aldrich, Munich, Germany). The specimen was centrifuged at
212006g for 30 min at 4uC. Homogenization was performed as
described previously [31]. Whole cell lysates were separated on
tris-glycine gels (Invitrogen, Karlsruhe, Germany) and transferred
onto a nitrocellulose membrane. Blots were incubated overnight
with rabbit polyclonal anti COX-2 serum (1:1250; 160126;
Cayman Chemical, Ann Arbor, Michigan) and then probed with
a goat anti-rabbit horseradish peroxidase coupled secondary
antibody (1:7500; Amersham, Little Chalfont, Buckinghamshire,
UK). An enhanced chemoluminescence system (Luminol reagent,
Santa Cruz, California) was used for visualization. For loading
control, membranes were stripped and reprobed (2 hours) with a
COX-2 Dependent CGRP Release in TGC
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Munich, Germany) followed by 2 hours incubation with goat anti-
mouse horseradish peroxidase coupled IgG (1:7500; Amersham,
Little Chalfont, Buckinghamshire, UK). For positive control
macrophage + IFNy/LPS cell lysate was used as provided by
the manufacturer (BDBiosciences, Heidelberg, Germany). Optical
density measurement for COX-2 was performed by dividing the
intensity of the COX-2 bands by the intensity of the house keeping
protein (b-Actin, 1:5000).
Immunohistochemistry
Trigeminal ganglia cell cultures (day 6) were incubated 6 or
24 hours with 10 ng/ml IL-1b or vehicle, subsequently rinsed with
PBS 0.1 M (pH 7.4) and fixed with methanol 100% for 15 min at
220u (n=4). Cells were washed 3 times with PBS 0.1 M and
blocked with normal donkey serum 10% and 0.3% Triton X in
0.1 M PBS for 2 hours at 4uC. For COX-2/CGRP and b-tubulin
III/GFAP co-staining cells were incubated overnight at 4uCi n
rabbit anti-COX-2 serum (diluted 1:300 in PBS; 160126; Cayman
Chemical, Ann Arbor, Michigan) or in rabbit anti-CGRP serum
(diluted 1:200 in PBS; C8198; Sigma Aldrich, Munich, Germany)
and in mouse anti-b-tubulin III serum (as a specific neuronal
marker) (diluted 1:600 in PBS; T5076; Sigma Aldrich, Munich,
Germany) or mouse anti glial fibrillary acidic protein (GFAP)
serum (as a glia marker) (diluted 1:300 in PBS; MAB360;
Chemicon) +3% normal donkey serum and 0.3% Triton X in
0.1 M PBS. The specimen was then washed 3610 min in PBS and
incubated for 90 min with Alexa Fluor 594 donkey anti-rabbit IgG
(diluted 1:600 in PBS; A-21207; Invitrogen, Karlsruhe, Germany)
and Alexa Fluor 488 donkey anti-mouse IgG (diluted 1:600 in
PBS; A-21202; Invitrogen, Karlsruhe, Germany) +3% normal
donkey serum and 0.3% Triton X in 0.1 M PBS at room
temperature.
Prior to use, all secondary antibodies were tested for non-
specific staining by omitting the primary antibodies in both IL-1b
and vehicle-treated cell cultures. Non-specific staining was not
observed with any of the secondary antibodies.
Cover slips were placed on slides, air-dried, mounted with a
glycerol-containing mounting medium (Mowiol, Calbiochem, Bad
Soden, Germany) and observed on a fluorescent microscope
(DMRA2, Leica GmbH, Wetzlar, Germany). Fluorescent images
were photographed by digital camera (DC300F, Leica GmbH,
Wetzlar, Germany) and captured with Leica DC Twain 5.1.10
(Leica GmbH, Wetzlar, Germany). Images were processed with
Photoshop 6.0 (Adobe, San Jose, CA, USA) to visualize co-
labelling by superimposing the digital images. Immunohistochem-
istry results of cell cultures were identical on day 2 and 6.
For co-staining of CGRP with COX-2 we used an Alexa Fluor
488 donkey anti-mouse IgG (A-21202; Invitrogen, Karlsruhe,
Germany) labeled rabbit anti-CGRP serum (diluted 1:200 in PBS;
C8198; Sigma Aldrich, Munich, Germany) and a rabbit anti-
COX-2 serum (diluted 1:300 in PBS) +3% normal donkey serum
and 0.3% Triton X in 0.1 M PBS. For labeling of the anti-CGRP
antibody we used the ApexTM Alexa Fluor 488 Antibody labeling
Kit according to the instructions of the manufacturer. Labeling
was performed to avoid cross binding with the use of the same
anti-CGRP and anti-COX-2 antibodies that were utilized in the
b-tubulin III/GFAP co-stainings before. Cells were incubated
overnight at 4uC and COX-2 antibodies were recognized by Alexa
Fluor 594 donkey anti-rabbit IgG (diluted 1:600 in PBS). All other
procedures (washing, incubation and mounting) were performed
as described above. Cover slips on slices were observed on a
fluorescent confocal microscope (Leica TCS SPE confocal
microscope; Leica Microsystems, Wetzlar, Germany). Images
were photographed by the system built in digital camera and
captured with Leica Confocal Software (Leica, Wetzlar, Ger-
many). Images were processed with ImageJ (National Institutes of
Health) to visualize co-labelling.
PGE2 determination by enzyme immunoassay
For PGE2 determination 6 day old cultured trigeminal ganglia
neurons were incubated with 10 ng/ml IL-1b or equal volume of
vehicle (PBS 0.1 M) for 30 min or 4 hours. For inhibition studies
cell cultures were preincubated for 15 min with sumatriptan
(10 mM), indomethacin (10 mM) or parecoxib (10 mMo r1mM)
prior to stimulation with IL-1b (10 ng/ml). In control experi-
ments, equal volumes of vehicle (PBS 0.1 M) were added at the
corresponding time. Prior to stimulation 50 ml supernatant of each
well were removed to assess baseline content of PGE2. 30 min or
4 hours after stimulation the supernatants of two dishes were
pooled and 100 ml of the supernatant were removed for PGE2
determination. PGE2 release was determined using a specific
PGE2 enzyme immunoassay (Cayman Chemical, Ann Arbor,
Michigan, USA) according to the manufacturer’s instructions. The
baseline samples of the two corresponding wells were also pooled
and PGE2 content was determined. All samples were measured in
duplicates. PGE2 release was determined in pg/ml as absolute
increase over baseline values in the corresponding two wells.
CGRP determination by enzyme immunoassay
After 6 days in culture the medium was gently removed and
replaced with fresh medium without NGF to exclude effects of
NGF on protein release. 1 hour later cells were stimulated with
IL-1b (10 ng/ml), PGE2 (100 nm or 10 mm) or equal volume of
Table 1. Sequences, cycling conditions and efficacies of all primers used in qRT-PCR.
Gene Primer (59-39) Den. Ann. Elo. Efficacy
CGRP forward AAG TTC TCC CCT TTC CTG GT
reverse GAG ACC TTC AAC ACC CCA GCC
95uC
15 s
66uC
10 s
72uC
15 s
1,918552
COX-1 forward TAA GTA CCA GGT GCT GGA TGG
reverse GGT TTC CCC TAT AAG GAT GAG
[59]
95uC
15 s
58uC
10 s
72uC 15 s 1,965760
COX-2 forward TGA TCG AAG ACT ACG TGC AAC AC
reverse CAG CAA TCT GTC TGG TGA ATG AC
95uC
15 s
63uC
10 s
72uC
10 s
1,702342
GAPDH forward AGA TTG GCA ATG CAT GC
reverse CCT TCT TGA TGT CAT CAT ACT TGG
95uC
15 s
63uC
10 s
72uC
10 s
1,816696
doi:10.1371/journal.pone.0017360.t001
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45 min before stimulation with sumatriptan (10 mM or 100 mM),
indomethacin (10 mM) or parecoxib (10 mM). Prior to stimulation
50 ml supernatant of each well were removed to assess baseline
content of CGRP. After 1, 4, 10 or 24 hours the supernatants of
two dishes were pooled and 100 ml were removed for CGRP
determination using a specific CGRP enzyme immunoassay
(SPIbio, Montigny le Bretonneux, France) as recommended by
the manufacturer. For each experiment, one set of wells was
treated with 60 mM KCl to determine the responsiveness of the
cultures to depolarizing stimuli as described previously [19].
Cultures that exhibited a response less than 2-fold on CGRP
release after the depolarizing stimulus were not analyzed. CGRP
release was determined in pg/ml as absolute increase over baseline
values in the corresponding two wells. All samples were measured
in duplicates.
Statistical analysis
For PCR statistical analysis was performed using variance
analysis followed by Bonferroni correction. For PGE2 and CGRP
studies values were first tested for normal distribution (Kolmo-
gorov-Smirnov test) followed by an unpaired t-test to detect
statistically significant differences between two groups using SPSS
17 statistical software (SPSS, Chicago, IL, USA). Statistical
significance was assumed when p,0.05. Data are shown as mean
6 standard error of the mean (SEM).
Results
Characterization of trigeminal ganglia cell culture
Trigeminal ganglia are a heterogeneous tissue containing
neuronal cells, satellite cells and Schwann cells. Neurons were
identified by their typical pseudo-unipolar morphology of sensory
neurons and by staining with the neuronal marker b-tubulin III.
Under our conditions the cell culture obtained from rat trigeminal
ganglia contained approximately 10% b-tubulin III positive
neurons. The rest of the cell population consisted of astrocytes
staining positive for GFAP. Most of the sensory neurons were
surrounded by GFAP positive glial cells (satellite glial cells).
IL-1b induces COX-2 mRNA
IncubationofculturedtrigeminalgangliacellswithIL-1b (10 ng/
ml) led to a time-dependent expression of COX-2 mRNA (Fig. 1A).
COX-2 mRNA was significantly (,4.5 fold) increased 90 min after
incubationwith IL-1b compared to vehicle(n=4; p,0.05).COX-2
mRNA expression peaked after 3 hours (,7 fold increase; n=5;
p,0.05) and declined after 6 hours but was still significantly (,3
fold; n=4; p,0.05) increased compared to vehicle stimulation.
To determine whether IL-1b induces COX-2 mRNA specifi-
cally, COX-1 mRNA expression was analyzed at the 3 hours time
point. There was no difference between COX-1 mRNA
expression in IL-1b (10 ng/ml) (0.4960.02 SEM fold increase;
n=3) and vehicle stimulated cells (0.3460.01 SEM fold increase;
n=3; p.0.05).
A dose response for IL-1b (1 pg/ml; 100 pg/ml; 10 ng/ml;
100 ng/ml) induced COX-2 gene expression was established at
3 hours since COX-2 mRNA expression was maximal at this time
point. Increasing doses of IL-1b resulted in increased COX-2
mRNA levels (Fig. 1B). Stimulation with 1 pg/ml IL-1b showed
no difference compared to stimulation with vehicle (n=4;
p.0.05). Higher doses of IL-1b (100 pg/ml; 10 ng/ml) led to a
significant increase of COX-2 mRNA expression. Further increase
of IL-1b doses (100 ng/ml) resulted in no further induction of
COX-2 mRNA (data not shown). As IL-1b 10 ng/ml caused a
reliable and strong COX-2 mRNA expression we used this dose
for all further experiments.
To confirm the specificity of IL-1b induced COX-2 mRNA the
IL-1 receptor antagonist (IL-1ra) (1 mg/ml) was added 15 min
Figure 1. Expression of COX-2 mRNA in trigeminal ganglia cell
culture following IL-1b incubation. Induction of COX-2 mRNA was
time (A) and dose dependent (at the 3 hours time point; B). COX-2
mRNA expression was maximal after 3 hours (A) and at the IL-1b dose
of 10 ng/ml (B) (n=4-5/group). Co-incubation with the IL-1ra led to a
significantly reduced COX-2 mRNA induction rate after 3 hours
indicating the specificity of the effect (C). Application of the IL-1ra +
vehicle resulted in a minor COX-2 mRNA induction rate comparable to
vehicle administration (n=3). Values are expressed as mean 6 SEM.
*p ,0.05 compared to vehicle.
doi:10.1371/journal.pone.0017360.g001
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reduced COX-2 expression rate: IL-1b plus vehicle resulted in a 7-
fold COX-2 mRNA increase after 3 hours whereas co-adminis-
tration with IL-1ra led to a 3.5-fold increase (n=4; p,0.05)
(Fig. 1C). Stimulation with IL-1b + IL-1ra was not significantly
different from vehicle + IL-1ra administration alone (p.0.05).
IL-1b induces COX-2 protein synthesis in neuronal and
glial cells
To show that enhanced COX-2 transcription leads to increased
protein synthesis western blot analysis was performed after
6 hours. Immunoblot analysis of IL-1b stimulated trigeminal
ganglia cell cultures (n=3) and the cell lysate (positive control)
revealed a single clear band after 6 hours at the size of
approximately 70 kDA corresponding to COX-2 protein
(Fig. 2A). In vehicle treated cultures (n=3) a faint COX-2 band
could be detected. However, there was a striking difference in
signal intensity in all three experiments (optical density 0.15 6
0.04 SD for vehicle vs. 0.48 6 0.09 SD for IL-1b treated cells;
p,0.05).
Induced COX-2 protein expression in trigeminal ganglia cell
cultures could also be observed by immunohistochemistry with a
COX-2 antibody 6 hours after treatment with IL-1b (10 ng/ml)
(Fig. 2B; n=4). Co-staining with mouse anti-b-tubulin III serum
(b-tub III) for the identification of neuronal cells or with mouse
anti-GFAP serum staining positive for glial cells revealed both
neuronal and glial cells as the cellular source for COX-2 protein
(Fig. 2B). Basal COX-2 expression could be observed in neuronal
and glial cells and induction of COX-2 expression was seen also in
both cell types. A strong induction of COX-2 was noted in
particular in large glial cells.
IL-1b induced PGE2 release is dependent on COX-2
activity
To assess whether IL-1b induced COX-2 expression is func-
tionally significant, PGE2 release into the supernatant was
determined by Enzyme immunoassay (EIA). PGE2 release was
measured before and after maximal induction of COX-2 mRNA
(3 hours after stimulation with IL-1b). PGE2 content in the
supernatant was not significantly different 30 mins after stimula-
tion with IL-1b (486261 SEM pg/ml (IL-1b) vs. 3326105 SEM
pg/ml (vehicle); n=4; p.0.05). In contrast, 4 hours after IL-1b
stimulation PGE2 concentration in the supernatant of IL-1b
treated cells was strongly elevated (18296640 SEM pg/ml) while
vehicle treatment was without effect (191681 pg/ml SEM; n=4;
p,0.05 (Fig. 3A).
The non-selective COX inhibitor indomethacin (10 mM) and
the selective COX-2 inhibitor parecoxib (10 mM) administered to
the supernatant of TGC 15 min prior to IL-1b exposure
completely aborted PGE2 release after 4 hours (Fig. 3B). Statistical
significant difference (p,0.05) was achieved for all groups vs. IL-
1b + vehicle (n=3–4/group). In contrast, sumatriptan (10 mM) did
neither affect IL-1b induced COX-2 mRNA synthesis nor PGE2
release (data not shown). 5-HT1B/D receptor expression in these
cells was detected by RT-PCR. Because selective and non-selective
COX-inhibitors block IL-1b induced PGE release we conclude
that PGE2 release from trigeminal ganglia cells is dependent on
COX-2 expression and function.
IL-1b induces delayed CGRP release in trigeminal ganglia
neurons
TGN release CGRP upon stimulation with e.g. potassium
chloride, a cocktail of inflammatory agents, capsaicin (Durham,
Figure 2. Expression of COX-2 protein in trigeminal ganglia
cells after IL-1b stimulation. COX-2 protein in cell culture homog-
enates was analyzed 6 hours after stimulation with IL-1b using Western
blot (n=3). A representative image is shown in panel A. Cell lysate of IL-
1b treated TGC and the positive control (IFNy/LPS treated macrophages)
showed a clear band at 70 kDa corresponding to COX-2 protein. Vehicle
stimulation resulted in a faint COX-2 expression. The expression of COX-2
protein in cultured trigeminal ganglia cells exposed 6 hours to vehicle
(10 ng/ml, upper panel B1-B3/B7-B9) or IL-1b (0.1 M PBS, lower panel B4-
B9/B10-B12) is shown in fluorescent micrographs in panel B. Cells were
stained with a mouse b-tubulin III antibody, indicative of neuronal cells
(B1 and B4) or a mouse GFAP antibody, indicative of glial cells (B7 and
B10), and a rabbit COX-2 antibody (B2, B5, B8, B11). The b-tubulin III and
the GFAP antibodies were recognized by an Alexa Fluor 488 labeled
secondary donkey anti-mouse antibody (green) and the COX-2 antibody
was recognized by an Alexa Fluor 594 labeled secondary donkey anti-
rabbit antibody (red). Double stained cells appear orange in B3, B6, B9
and B12. IL-1b caused a clear upregulation of COX-2 in neuronal and glial
cells (lower panel) whereas a faint COX-2 expression could also be
observed in control experiments (upper panel). The strongest induction
of COX-2 was seen in bigger glial cells (40-100 mm) and neuronal cells.
doi:10.1371/journal.pone.0017360.g002
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1b activates trigeminal ganglia neurons (TGN) to release CGRP
we studied CGRP concentrations in the supernatant. 24 hours
after stimulation CGRP levels were significantly increased
compared to vehicle (466644 SEM pg/ml IL-1b vs. 238629
SEM pg/ml vehicle; p,0.05 n=12). CGRP was not different 1, 4
and 10 hours after stimulation with IL-1b (10 ng/ml) compared to
vehicle, but a trend towards enhanced CGRP release was seen
after 10 hours (2266101 SEM pg/ml (IL-1b) vs. 115626 SEM
pg/ml (vehicle); p.0.05; n=4) (Fig. 4A).
By using quantitative real-time PCR we further assessed
whether the stimulation with 10ng/ml IL-1b also leads to
increased transcription of CGRP. We could not observe any
differences of CGRP mRNA content between vehicle and IL-1b
treated cultures after 1 h, 4 h, 10 h or 24 h (p.0.05; n=4; data
not shown).
To show that CGRP is derived from neurons we co-stained the
cultures with CGRP- and b-tub III antibodies 24 hours after
exposure to IL-1b or vehicle. All CGRP stained cells also stained
positive for b-tub III, clearly indicating that CGRP is expressed by
neuronal cells. CGRP could be detected in the cell body and
neuronal processes (Fig. 4B). As seen previously in other trigeminal
ganglia cell culture studies [19,32] almost all neurons stained
positive for CGRP, whereas in vivo in rat and human only
approximately 23-50% of all trigeminal ganglia neurons contain
CGRP [33,34]. All neurons staining positive for CGRP were also
positive for COX-2, whereas glial cells did only stain positive for
COX-2 (Fig. 4C).
IL-1b induced CGRP release in in trigeminal ganglia
neurons is COX-2 dependent
To analyze whether IL-1b induced CGRP release is affected by
COX-2 activity, trigeminal ganglia cells were incubated 45 min
prior to stimulation with IL-1b with 10 mM indomethacin or
10 mm parecoxib. Both COX inhibitors blocked enhanced CGRP
release after 24 hours (548670 SEM pg/ml for IL-1b + vehicle
(n=10) vs. 326652 SEM pg/ml for IL-1b + parecoxib (n=7;
p,0.05) and 313675 SEM pg/ml for IL-1b + indomethacin
(n=4; p,0.05)). There were no significant differences between
CGRP release in the IL-1b + COX-inhibitor groups and vehicle +
vehicle stimulation (257640 SEM pg/ml; n=10; p.0.1).
Incubation with Sumatriptan 10 mM did not block IL-1b induced
CGRP release (4796147 SEM pg/ml; p.0.1; n=4) (Fig. 4C).
Incubation with a higher dose of sumatriptan (100 mM) did also
not change CGRP release in preliminary experiments.
To determine if the same population of trigeminal ganglia
neurons expresses CGRP and COX-2, we co-stained trigeminal
IL-1b treated (6 hours) trigeminal ganglia cell cultures with
CGRP- and COX-2-antibodies. Immunohistochemistry revealed
that all neuronal cells expressing COX-2 also stained positive for
CGRP, whereas glial cells only stained positive for COX-2
(Fig. 4D).
PGE2 stimulation causes CGRP release in in trigeminal
ganglia neurons
We could show before that IL-1b induces PGE2 release in TGC
and activates TGN to release CGRP. To determine whether
PGE2 directly activates TGN as determined by CGRP release,
cultured trigeminal ganglia cells were stimulated for 1 hour and
4 hours using two different PGE2 concentrations (100 nm and
10 mm). One hour after stimulation with 10 mm PGE2 the CGRP
concentration in the supernatant was significantly increased
(101632 SEM pg/ml for PGE2 vs. 2368 SEM pg/ml for vehicle;
p,0.05; n=5) and further increased after 4 hours (655695 SEM
pg/ml for PGE2 vs. 94614 SEM pg/ml for vehicle; p,0.05;
n=7). A lower dose of PGE2 (100 nM) led to a minor but still
significantly increased CGRP concentration after 1 hour (117645
SEM pg/ml; p,0.05 vs. vehicle; n=6) and after 4 hours
(4476122 SEM pg/ml; p,0.05; n=5) (Fig. 5A).
There was no effect of the COX inhibitors on PGE2 function in
this paradigm. We added 10 mm parecoxib (45 min) prior to
stimulation with PGE2 to the cultures, which did not alter CGRP
release after 1 hour and 4 hours compared to vehicle (n=3–4;
P.0.1). There was also no effect on CGRP release by pre-
stimulation with sumatriptan 10 mM (Fig. 5B) and 100 mM (Data
not shown).
Discussion
We have shown that cultured primary trigeminal ganglia
neurons and glial cells express COX-2 upon stimulation with
IL-1b in a dose and time dependent manner leading to PGE2
synthesis and protracted CGRP release in trigeminal ganglia
Figure 3. Induction of PGE2 levels in trigeminal ganglia cell
culture after stimulation with IL-1b. PGE2 levels were significantly
increased in TGC 4 hours after stimulation with IL-1b (10 ng/ml)
compared to vehicle (A). No effect on PGE2 release was seen 30
minutes after stimulation with IL-1b compared to vehicle (n=4/group).
Dependency of IL-1b induced PGE2 release on COX-2 activity is shown
in (B). 15 min of incubation with the selective (parecoxib, 10 mM) or the
non-selective (indomethacin, 10 mM) COX-2 inhibitor completely
aborted IL-1b induced PGE2 release after 4 hours. PGE2 levels are
illustrated as mean pg/ml 6 SEM compared to baseline. *p,0.05
compared to vehicle (n=3-4/group).
doi:10.1371/journal.pone.0017360.g003
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selective and non-selective COX-2 inhibitors thereby demonstrat-
ing dependency on COX-2 enzyme activity. Neither PGE2 nor
CGRP release were mediated by activation of 5-HT1B/D receptors
as the pre-incubation with sumatriptan was without effect.
The trigeminal ganglion (TG) is known to play a key role in the
pathophysiology of migraine and other primary headaches. Cultured
sensory neurons derived from trigeminal or dorsal root ganglia have
been shown to express the characteristics of ‘‘differentiated pain
sensory’’ cells [28]. Cultured TG cells have been used to illustrate
molecular mechanisms related to migraine pathophysiology e.g.
5-HT1B/D controlled CGRP release [19–21,35,36].
For stimulation we used IL-1b, a pro-inflammatory cytokine of
significant importance in models of inflammatory pain [2,27,37]
and sensitization [38]. IL-1b has been shown to activate
nociceptors to induce pain hypersensitivity in a rat skin nerve
preparation [38]. In inflammatory pain IL-1b was identified as the
key mediator to induce COX-2 in spinal cord [27] and in cultured
dorsal root ganglia cells [39–42]. The observation that IL-1b is
elevated in plasma during a migraine attack points to an
involvement in migraine pathophysiology [5,6]. High levels of
chemokines could stimulate the activation of trigeminal nerves and
the release of vasoactive peptides, resulting in inflammation [43].
IL-1b induced COX-2 and PGE2 synthesis resulting in
CGRP release
Stimulation of trigeminal ganglia cells with IL-1b led to a strong
induction of COX-2 mRNA and protein with subsequently PGE2
synthesis. Direct stimulation of TG cells with PGE2 resulted in
enhanced CGRP release in trigeminal ganglia neurons after one hour
and more pronounced after 4 hours. In an in vitro preparation of the
rat skull fluid-filled cavities electrical and chemical activation of
trigeminal afferents resulted in enhanced release of PGE2 and CGRP
from rat dura mater encephali [44] In a rat trigeminal ganglion cell
culture model Jenkins and co-workers identified the EP-2 receptor as
the key signaling mechanism for PGE2 induced CGRP release [45].
Enhancement of capsaicin induced CGRP release by PGE2 has been
observed in slices of the trigeminal nucleus caudalis, indicating a
prostaglandin induced neuronal sensitization [46].
While these observations may support a role of PGE2 in
neurogenic inflammation, it is uncertain which COX isoform
accounts for the PGE2 release. Since COX-1 is constitutively
Figure 4. IL-1b induced CGRP release in TGN is dependent on COX-2 activity but not on 5-HT1B/D receptor activation. A: IL-1b (10 ng/
ml) but not vehicle stimulation for 1, 4, 10 (n=4) or 24 hours (n=12) resulted in significantly enhanced CGRP levels in the supernatant of cultured
trigeminal ganglia cells at the 24 hrs time point (* p,0.05 vs. vehicle). Earlier time points did not show a significant difference between groups. CGRP
release is shown as mean pg/ml 6 SEM compared to baseline. Panel B shows a representative fluorescent photomicrograph of trigeminal ganglia
cells exposed 24 hours to IL-1b (10 ng/ml). Cells were stained with a mouse b-tubulin III antibody, which specifically recognizes neuronal cells (1) and
a rabbit CGRP antibody (2). b-tubulin III staining was visualized with an Alexa 488 donkey anti-mouse IgG antibody (green, panel 1). CGRP IgG was
recognized by Alexa 594 donkey anti-rabbit antibody (red, panel 2). All CGRP expressing cells stained positive for b-tubulin III (orange, panel 3). C: For
inhibition experiments TGC were exposed to either parecoxib (10 mM), sumatriptan ( mM), indomethacin (10 mM) or vehicle 45 min prior to 24 h
stimulation with IL-1b (10 ng/ml). Incubation with parecoxib (n=7) and indomethacin (n=4) blocked CGRP release in the supernatant significantly
compared to IL-1b + vehicle (n=10). Sumatriptan had no effect in the same paradigm (n=4). CGRP release is shown as mean pg/ml 6 SEM compared
to baseline. * p,0.05 compared to IL-1b + vehicle. D: Immunofluorescence staining shows that CGRP is co-expressed with COX-2 in trigeminal
ganglia neurons (n=3). Cultured trigeminal ganglia cells were exposed to IL-1b (10 ng/ml) for 6 hrs. Cells were stained with an Alexa Fluor 488
donkey anti-mouse IgG labeled rabbit anti-CGRP serum (green, panel 1) and with a rabbit anti-COX-2 antibody, which was recognized by an Alexa
Fluor 594 labeled secondary donkey anti-rabbit antibody (red, panel 2). Double stained cells appear orange (panel 3). All CGRP synthesizing cells also
stained positive for COX-2. Additionally COX-2 was expressed in glial cells not staining positive for CGRP.
doi:10.1371/journal.pone.0017360.g004
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and PGE2 release occurs immediately after electrical and chemical
meningeal stimulation [44] COX-1 may account for this response.
In our model, immediate PGE2 release did not occur after
stimulation with IL-1b. Additionally, COX-1 mRNA remained
unchanged 3 hours after stimulation with IL-1b. In contrast, IL-
1b induced COX-2 mRNA expression after 3 hours and PGE2
release after 4 hours. PGE2 release could be blocked by the
selective COX-2 inhibitor parecoxib. These findings provide
evidence for a COX-2 mediated pathway.
Glia-neuron interaction
We found neuronal and glial cells as a source of COX-2 as
demonstrated by immunohistochemistry. In particular, a strong
stimulus dependent induction of COX-2 by IL-1b was seen in large
glial cells. Stimulation of cultured trigeminal cells with PGE2 and
IL-1b ledto CGRP release exclusivelyintrigeminal ganglianeurons
(cell body and neuronal processes). Immunohistochemistry did not
reveal any CGRP expression in glial cells which is in line with the
findings of others in rat and human trigeminal ganglia [34].
Our findings support a glia-neuron interaction within the
trigeminal ganglion. We hypothesize that IL-1b activates glial cells
and neurons in the trigeminal ganglion, which leads to the
expression of COX-2 in these cells. In turn the COX-2 reaction
product PGE2 activates trigeminal neurons to release CGRP.
Glia-neuron interaction plays an important role for the normal
function of the brain as well in the pathophysiology of many CNS
diseases [47]. Over the last years the importance of CNS glia for
neuronal function in pain processing has been demonstrated in
various experimental pain states [48]. The physiological function of
Figure 5. CGRP release in the supernatant of cultured
trigeminal ganglia cells after stimulation with PGE2.A : PGE2
stimulation (100 nM and 10 mM) increased CGRP levels within the
supernatant time and dose dependently after 1 hour (n=5/group) and
more pronounced after 4 hours compared to vehicle (n=7/group).
B: Incubation with 10 mM parecoxib and sumatriptan (10 mM and
100 mM [not shown]) did not alter PGE2 release compared to incubation
with vehicle (n=3-4). CGRP is shown as mean pg/ml 6 SEM compared
to baseline. * p,0.05 compared to vehicle. # p.0.1 compared to PGE +
vehicle.
doi:10.1371/journal.pone.0017360.g005
Figure 6. COX-2 dependent induction of CGRP release in
trigeminal ganglia neurons. Stimulation with IL-1b leads to the
synthesis of COX-2 in trigeminal neurons and glial cells followed by
PGE2 release. PGE2 in turn activatesTGN to release CGRP. PGE2 and
CGRP release can be blocked by selective (parecoxib) or non-selective
(indomethacin) COX-2 inhibitors. The attenuation of CGRP and PGE2
release could contribute to the effect of COX-inhibitors to revoke
sensitization and to abort pain.
doi:10.1371/journal.pone.0017360.g006
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the trigeminal ganglia cell bodies of neurons are surrounded by
satellite glial cells that can modulate their function and enhance their
excitability [49]. In a recently published work IL-1b induced COX-2
expression and PGE2 synthesis in cultured trigeminal satellite cells.
Stimulation of TGN with conditioned media from these activated
satellite cells led to sensitization of TGN resulting in increased CGRP
release after stimulation with capsaicin [50]. Activation of satellite
glial cells in the trigeminal ganglion modulates the excitability of TG
neurons via IL-1b following inflammation associated with hyperal-
gesia in rats [51]. The involvement of neuron-glia signaling via gap
junctions and release of nitric oxide and pro-inflammatory cytokines
from the trigeminal ganglia satellite glial cells has been demonstrated
recently in experimental models related to migraine pathophysiology
[52–55]. Interestingly, CGRP receptors are expressed on trigeminal
neurons and glial cells. CGRP released by trigeminal ganglia neurons
has been shown to function in a paracrine manner to activate
trigeminal satellite glial cells to release various cytokines including IL-
1b and nitric oxide, a molecule known to be involved in migraine
pathophysiology [52,54]. Additionally CGRP possesses autocrine
signaling function properties to increase mRNA levels of CGRP in
cultured trigeminal neurons [35]. Our finding that induction of
COX-2 expression by IL-1b in trigeminal glial and neuronal cells
leads to direct induction of CGRP release from trigeminal neurons
supports the notion of an important cross talk between neurons and
glial cells in the trigeminal ganglion in processes involved in
trigeminally mediated headaches.
IL-1b induced CGRP release in trigeminal ganglia neurons
In our model exposure of trigeminal ganglia cell culture to IL-1b
led directly to delayed CGRP release from TGN 24 hours after
stimulationwithanearliernon-significanttrendafter10 hours.This
latency was not expected as IL-1b induced PGE2 release was
significant after 4 hours and PGE2 caused CGRP release after
1 hour. Delayed (24 hours) IL-1b induced CGRP release was
observed previously in dorsal root ganglia neurons. Blocking
experiments demonstrated that IL-1b might activate proteinkinase
C that in turn initiates c-Jun-N-terminal kinase mitogen activated
protein kinase followed by activation of nuclear factor-kappaB,
which finally induces alpha-CGRP gene expression and neuropep-
tide release from these sensoryneurons [56]. In our hands IL-1b did
not lead to an induction of CGRP mRNA synthesis in cultured
trigeminal neurons as demonstrated by quantitative RT-PCR. We
speculate that a certain threshold of PGE2 concentration in the
supernatant isnecessaryto induce gradualCGRPexpression,which
may take several hours to archive. Direct stimulation of TG with
10 mm PGE2 did also not lead to the induction of CGRP gene
expression. In line, in another rat model of isolated trigeminal
ganglionthe infusionoftheNO donorglyceroltrinitrate inducedthe
release of CGRP but did not change mRNA levels of CGRP [57].
Therefore, elevated CGRP release in the trigeminal ganglion in our
and other models seems to be dependent on enhanced secretion
rather than synthesis due to gene expression.
Non-selective (indomethacin) and selective (parecoxib) COX-2
inhibitors aborted L-1b induced CGRP release. In contrast,
neither IL-1b nor PGE2 induced CGRP release could be blocked
by sumatriptan, indicating a release mechanism independent of 5-
HT1B/D receptor activation. A COX-2 dependent CGRP release
could also be demonstrated in the dura mater in an isolated
preparation of fluid-filled rat skull cavities. The COX-2 inhibitor
S-flurbiprofen inhibited inflammatory mediator (bradykinin,
histamine and serotonin) induced CGRP and PGE2 release while
the 5-HT1B/D receptor agonist naratriptan was without effect [58].
Our findings demonstrate a direct link between COX-2 activity
and CGRP release in TGN. In a slightly different cell culture
model of trigeminal ganglia cells potassium chloride and
inflammatory cocktail induced rapid CGRP release that could
be blocked by sumatriptan [19]. The results of our study point to
an alternative pathway of cytokine induced CGRP release in TGN
regulated by COX-2 and not affected by sumatriptan.
Conclusion
In summary, our results demonstrate that primary trigeminal
ganglia cells are able to synthesize COX-2 and PGE2 upon
stimulation with the cytokine IL-1b in a functionally significant
mode resulting in delayed CGRP release in trigeminal ganglia
neurons. CGRP release is mediated by a COX-2 dependent
pathway and independent of 5-HT1B/D receptor activation (Fig. 6).
COX-2 expression in trigeminal ganglion cells could contribute
to the development of pain in trigeminal mediated headaches.
Non-selective [23] and selective COX-2 inhibitors [24,25] abort
migraine attacks. The demonstrated attenuation of CGRP release
by COX-2 inhibition could at least in part explain the mechanism
of COX inhibitors in migraine therapy.
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